235 related articles for article (PubMed ID: 18071305)
1. Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer.
Yu S; Wong YC; Wang XH; Ling MT; Ng CF; Chen S; Chan FL
Oncogene; 2008 May; 27(23):3313-28. PubMed ID: 18071305
[TBL] [Abstract][Full Text] [Related]
2. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
3. Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues.
Cheung CP; Yu S; Wong KB; Chan LW; Lai FM; Wang X; Suetsugi M; Chen S; Chan FL
J Clin Endocrinol Metab; 2005 Mar; 90(3):1830-44. PubMed ID: 15598686
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of p21(WAF1/CIP1) levels leads to growth suppression of prostate cancer cell lines.
Sugibayashi R; Kiguchi Y; Shimizu T; Suzuki T; Hamada H; Takeda K
Anticancer Res; 2002; 22(2A):713-9. PubMed ID: 12014641
[TBL] [Abstract][Full Text] [Related]
6. Orphan nuclear receptor TLX functions as a potent suppressor of oncogene-induced senescence in prostate cancer via its transcriptional co-regulation of the CDKN1A (p21(WAF1) (/) (CIP1) ) and SIRT1 genes.
Wu D; Yu S; Jia L; Zou C; Xu Z; Xiao L; Wong KB; Ng CF; Chan FL
J Pathol; 2015 May; 236(1):103-15. PubMed ID: 25557355
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Zhuang SH; Burnstein KL
Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
[TBL] [Abstract][Full Text] [Related]
8. CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.
Chen M; Ni J; Chang HC; Lin CY; Muyan M; Yeh S
Carcinogenesis; 2009 May; 30(5):841-50. PubMed ID: 19126643
[TBL] [Abstract][Full Text] [Related]
9. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc.
Wang LG; Liu XM; Fang Y; Dai W; Chiao FB; Puccio GM; Feng J; Liu D; Chiao JW
Int J Oncol; 2008 Aug; 33(2):375-80. PubMed ID: 18636159
[TBL] [Abstract][Full Text] [Related]
10. ERRβ splice variants differentially regulate cell cycle progression.
Heckler MM; Riggins RB
Cell Cycle; 2015; 14(1):31-45. PubMed ID: 25496115
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.
Hååg P; Bektic J; Bartsch G; Klocker H; Eder IE
J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):251-8. PubMed ID: 15982869
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-related receptor-gamma and peroxisome proliferator-activated receptor-gamma coactivator-1alpha regulate estrogen-related receptor-alpha gene expression via a conserved multi-hormone response element.
Liu D; Zhang Z; Teng CT
J Mol Endocrinol; 2005 Apr; 34(2):473-87. PubMed ID: 15821111
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors.
Lu D; Kiriyama Y; Lee KY; Giguère V
Cancer Res; 2001 Sep; 61(18):6755-61. PubMed ID: 11559547
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.
Shiota M; Yokomizo A; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Fujimoto N; Seki N; Naito S
Mol Endocrinol; 2010 Jan; 24(1):114-27. PubMed ID: 19884383
[TBL] [Abstract][Full Text] [Related]
15. ERRα augments HIF-1 signalling by directly interacting with HIF-1α in normoxic and hypoxic prostate cancer cells.
Zou C; Yu S; Xu Z; Wu D; Ng CF; Yao X; Yew DT; Vanacker JM; Chan FL
J Pathol; 2014 May; 233(1):61-73. PubMed ID: 24425001
[TBL] [Abstract][Full Text] [Related]
16. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells.
Liu PY; Chan JY; Lin HC; Wang SL; Liu ST; Ho CL; Chang LC; Huang SM
Mol Cancer Res; 2008 Jul; 6(7):1204-14. PubMed ID: 18644983
[TBL] [Abstract][Full Text] [Related]
18. Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma.
Zuercher WJ; Gaillard S; Orband-Miller LA; Chao EY; Shearer BG; Jones DG; Miller AB; Collins JL; McDonnell DP; Willson TM
J Med Chem; 2005 May; 48(9):3107-9. PubMed ID: 15857113
[TBL] [Abstract][Full Text] [Related]
19. Activation of the orphan nuclear receptor RORalpha induces growth arrest in androgen-independent DU 145 prostate cancer cells.
Moretti RM; Marelli MM; Motta M; Polizzi D; Monestiroli S; Pratesi G; Limonta P
Prostate; 2001 Mar; 46(4):327-35. PubMed ID: 11241556
[TBL] [Abstract][Full Text] [Related]
20. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism.
Mottet D; Pirotte S; Lamour V; Hagedorn M; Javerzat S; Bikfalvi A; Bellahcène A; Verdin E; Castronovo V
Oncogene; 2009 Jan; 28(2):243-56. PubMed ID: 18850004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]